Lupus nephritis
Conditions
Interventions
None listed
Sponsors
CHUGAI PHARMACEUTICAL CO.,LTD. Nippon Shinyaku Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: LN Patients treated with induction treatment and meet all of the following (1) to (8): (1) Diagnosed with lupus nephritis (defined as 7100007 excluding suspected cases in a disease code) for at least 2 months between May 2016 and March 2023 (2) Prescription of oral GC or steroid pulse therapy at the dose of 20 mg/day or more with a disease code 7100007 (lupus nephritis) issued in the same month (3) Observable for at least 90 days prior to Index Date (4) Observable for at least 540 days after the Index Date (5) No oral GC or steroid pulse therapy 20 mg/day or more for 90 days prior to the Index Date (6) Urinalysis was performed and the month in which a disease code 7100007 excluding suspected cases was given at least 2 months within 360 days after the Index Date (7) Anti-DNA antibody test was performed and the month in which a disease code 7100007 excluding suspected cases was given at least 2 months within 360 days after the Index Date (8) Complement Blood test was performed and the month in which a disease code 7100007 excluding suspected cases was given at least 2 months within 360 days after the Index Date Dose of oral GC and steroid pulse are converted equivalent to prednisolone. The Index Date shall be the date of the first date meeting the following conditions. Date of prescription of oral GC 20 mg/day or more or date of first prescription of steroid pulses in the same month in which a disease code 7100007 excluding suspected cases was given.
Exclusion criteria
Exclusion criteria: Not applicable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients on oral GC 5 mg/day or less (prednisolone equivalent) after 540 days from the Index Date | — |
Countries
Japan
Contacts
Public ContactTsutomu Urakawa
CHUGAI PHARMACEUTICAL CO.,LTD. Medical Affairs Div.
Outcome results
None listed